Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial.

@article{Mitsudomi2010GefitinibVC,
  title={Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial.},
  author={Tetsuya Mitsudomi and Satoshi Morita and Yasushi Yatabe and Shunichi Negoro and Isamu Okamoto and Junji Tsurutani and Takashi Seto and Miyako Satouchi and Hirohito Tada and Tomonori Hirashima and Kazuhiro Asami and N Katakami and Minoru Takada and Hiroshige Yoshioka and Kazuhiko Shibata and Shinzoh Kudoh and Eiji Shimizu and Hiroshi Saito and Shinichi Toyooka and Kazuhiko Nakagawa and Masahiro Fukuoka},
  journal={The Lancet. Oncology},
  year={2010},
  volume={11 2},
  pages={121-8}
}
BACKGROUND Patients with non-small-cell lung cancer harbouring mutations in the epidermal growth factor receptor (EGFR) gene respond well to the EGFR-specific tyrosine kinase inhibitor gefitinib. However, whether gefitinib is better than standard platinum doublet chemotherapy in patients selected by EGFR mutation is uncertain. METHODS We did an open label, phase 3 study (WJTOG3405) with recruitment between March 31, 2006, and June 22, 2009, at 36 centres in Japan. 177 chemotherapy-naive… CONTINUE READING
Highly Influential
This paper has highly influenced 86 other papers. REVIEW HIGHLY INFLUENTIAL CITATIONS

Citations

Publications citing this paper.
Showing 1-10 of 1,453 extracted citations

Personalized Targeted Therapy for Lung Cancer

International journal of molecular sciences • 2012
View 5 Excerpts
Highly Influenced

Non-Small Cell Lung Cancer: The Challenges of the Next Decade

Front. Oncol. • 2011
View 12 Excerpts
Highly Influenced

Phase II study of nedaplatin and docetaxel in patients with advanced squamous cell carcinoma of the lung.

Annals of oncology : official journal of the European Society for Medical Oncology • 2011
View 9 Excerpts
Highly Influenced

Consequences of targeted treatments for second-line therapy.

Annals of oncology : official journal of the European Society for Medical Oncology • 2010
View 5 Excerpts
Highly Influenced

Biochemical Basis and Therapeutic Implications of Angiogenesis

Advances in Biochemistry in Health and Disease • 2017
View 14 Excerpts
Highly Influenced

References

Publications referenced by this paper.
Showing 1-10 of 37 references

Clinical outcomes of patients with epidermal growth factor receptor (EGFR) mutations (Mut) in IPASS IRESSATM Pan Asia Study

TS Mok, KF To, V Srimunimimit
J Thorac Oncol • 2009

Combined survival analysis of prospective clinical trials of gefitinib for non-small cell lung cancer with EGFR mutations.

Clinical cancer research : an official journal of the American Association for Cancer Research • 2009

Effi cacy and safety of erlotinib as fi rst - line maintenance in NSCLC following non - progression with chemotherapy : results from the phase III SATURN study

F Cappuzzo, BP Coudert, R Wierzbicki
Eur J Cancer • 2009

The diff erential effi cacy of pemetrexed according to NSCLC histology : a review of two phase III studies

RS Herbst, JV Heymach, SM Lippman
Oncologist • 2009

tinib in individuals with non-small cell lung cancer

F Cappuzzo, BP Coudert, R Wierzbicki
Eur J Cancer • 2009

Similar Papers

Loading similar papers…